AZN.L: Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

UK Markets closed

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed price. Currency in GBp
Add to watchlist
4,686.50-1.50 (-0.03%)
At close: 5:08PM BST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close4,688.00
Open4,666.50
Bid4,650.00 x 6100
Ask4,720.00 x 13000
Day's range4,666.50 - 4,768.25
52-week range3,680.00 - 5,505.00
Volume1,855,133
Avg. volume2,519,135
Market cap59.31B
Beta0.61
PE ratio (TTM)16.98
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield2.80 (4.81%)
Ex-dividend dateN/A
1y target estN/A
  • Market Realist2 hours ago

    What Analysts Recommend for AstraZeneca

    Wall Street analysts estimate that AstraZeneca’s (AZN) top line will rise 8.0% to ~$4,742 million in 1Q17.

  • Reuters3 hours ago

    New GlaxoSmithKline CEO wants fewer, bigger new drug launches

    GlaxoSmithKline's new chief executive aims to improve returns in drug development, and wants fewer but bigger new medicine launches. In her first comments since taking over on April 1, Emma Walmsley, 47, said on Wednesday that her priority was the pharmaceuticals unit, where she wants commercial considerations to be given greater weight in early investment decisions. "We'd like to have probably fewer and more focused priorities, to have bigger launches," she told reporters, after announcing first-quarter results, adding this would involve tough choices and the closure of some research programmes.

  • Reuters - UK Focus3 hours ago

    New GlaxoSmithKline CEO wants fewer, bigger new drug launches

    GlaxoSmithKline (Other OTC: GLAXF - news) 's new chief executive aims to improve returns in drug development, and wants fewer but bigger new medicine launches. In her first comments since taking over on April 1, Emma Walmsley, 47, said on Wednesday that her priority was the pharmaceuticals unit, where she wants commercial considerations to be given greater weight in early investment decisions. "We'd like to have probably fewer and more focused priorities, to have bigger launches," she told reporters, after announcing first-quarter results, adding this would involve tough choices and the closure of some research programmes.